3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
12
Squamous Cell Carcinoma of Head and Neck
11
Prostatic Neoplasms
11
Neoplasms
10
Breast Neoplasms
8
Stomach Neoplasms
7
Recurrence
7
Ovarian Neoplasms
7
Lung Neoplasms
7
Leukemia, Myeloid, Acute
7
Head and Neck Neoplasms
7
Myasthenia Gravis
6
Colorectal Neoplasms
6
Pancreatic Neoplasms
5
Oropharyngeal Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Fatigue
5
Urinary Bladder Neoplasms
4
Mouth Neoplasms
4
Melanoma
4
Fallopian Tube Neoplasms
4
Colonic Neoplasms
4
Cholangiocarcinoma
4
Rectal Neoplasms
3
Peritoneal Neoplasms
3
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphangioma, Cystic
×
90 days
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled